Completed PHASE3 INTERVENTIONAL 2-arm NCT01553981

A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

Sponsor: Sanjay Gandhi Postgraduate Institute of Medical Sciences

Updated 6 times since 2017 Last updated: Apr 20, 2015 Started: Mar 31, 2012 Primary completion: Apr 30, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01553981, this PHASE3 trial focuses on Lung Diseases, Interstitial and remains completed. Sponsored by Sanjay Gandhi Postgraduate Institute of Medical Sciences, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Data source: Sanjay Gandhi Postgraduate Institute of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lucknow, India